You are here

Article Text

Article menu
Download PDFPDF
Image of the moment
Capecitabine leukoencephalopathy
  1. Zeid Yasiry1,
  2. Mahdia S Obeda2,
  3. Ruth Batty3,
  4. Basil Sharrack1
  1. 1 Department of Neurology, Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Sheffield, UK
  2. 2 University of Sheffield Medical School, Sheffield, UK
  3. 3 Sheffield Teaching Hospital NHS Trust, Sheffield, UK
  1. Correspondence to Dr Zeid Yasiry, Department of Neurology, Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; zeid.yasiry{at}nhs.net

http://dx.doi.org/10.1136/practneurol-2018-002121

Statistics from Altmetric.com

    A 54-year-old man presented with a 2-day history of impaired concentration, dysgraphia, dysarthria and ataxia but with no focal sensory or motor deficit. Seven days before, he had received his first cycle of chemotherapy with capecitabine to treat adenocarcinoma of the gall bladder, identified at cholecystectomy. Since the start of the treatment he had felt tired and ‘spaced out’, and reported that he finally had driven his car into a wall when trying to park outside his house. He had a history of ulcerative colitis, hypercholesterolaemia and obstructive sleep apnoea. He was taking capecitabine (2800 mg two times per day), mesalazine, domperidone, fluoxetine and atorvastatin.

    On examination, he had broken persuit eye movements, mild left upper motor neurone facial weakness, mild right hand weakness, incoordination of …

    View Full Text

    Footnotes

    • Contributors ZY and MSO contributed to the original write-up of the manuscript. ZY, RB and BS contributed to patient care and revision of the manuscript in their respective specialty. RB provided the high-quality images and the figure captions.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned. Externally peer reviewed by Jeremy Rees, London, UK.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

    Other content recommended for you